For the quarter ending 2025-10-31, ALZN had -$1,171,439 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-10-31 | 2025-07-31 |
|---|---|---|
| Purchase of equipment | - | 0 |
| Net cash used in investing activities | - | 0 |
| Interest expense - debt discount | - | 0 |
| Net loss | -3,703,442 | -2,702,684 |
| Depreciation expense | 27,685 | 27,685 |
| Stock-based compensation to employees and consultants | 31,514 | 42,902 |
| Prepaid expenses and other current assets | -35,943 | 79,239 |
| Accounts payable and accrued liabilities | -265,823 | 348,550 |
| Net cash used in operating activities | -1,171,439 | -2,362,786 |
| Net proceeds from the issuance of preferred stock, net | - | 4,035,000 |
| Net proceeds from the issuance of preferred stock | 4,035,000 | - |
| Net cash provided by financing activities | 0 | 4,035,000 |
| Net increase in cash | -1,171,439 | 1,672,214 |
| Cash and cash equivalents at beginning of period | 3,948,658 | - |
| Cash and cash equivalents at end of period | 4,449,433 | - |
Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro, Inc. (ALZN)